OTCMKTS:CPMV Mosaic ImmunoEngineering 4/15/2025 Earnings Report $0.79 +0.39 (+97.21%) As of 09/5/2025 12:36 PM Eastern ProfileEarnings History Mosaic ImmunoEngineering EPS ResultsActual EPS-$0.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMosaic ImmunoEngineering Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMosaic ImmunoEngineering Announcement DetailsQuarterDate4/15/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsMosaic ImmunoEngineering's next earnings date is estimated for Monday, November 17, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Mosaic ImmunoEngineering Earnings HeadlinesMosaic ImmunoEngineering, Inc. (CPMV) - Yahoo FinanceJune 27, 2025 | au.finance.yahoo.comMosaic ImmunoEngineering, Inc. (CPMV)November 17, 2024 | finance.yahoo.comScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions of Americans at risk of blackouts and could lead to a crisis "many times worse than 2008" if not fixed.September 6 at 2:00 AM | Altimetry (Ad)Mosaic Co.November 5, 2024 | wsj.comMosaic ImmunoEngineering (OTC:CPMV) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comCowpea Mosaic Virus Nanoparticles Show Promise in Preventing Metastatic CancersMay 14, 2024 | msn.comSee More Mosaic ImmunoEngineering Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mosaic ImmunoEngineering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mosaic ImmunoEngineering and other key companies, straight to your email. Email Address About Mosaic ImmunoEngineeringMosaic ImmunoEngineering (OTCMKTS:CPMV), Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.View Mosaic ImmunoEngineering ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why DocuSign Could Be a SaaS Value Play After Q2 EarningsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Upcoming Earnings Synopsys (9/9/2025)Oracle (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
